U.S. equities finished lower across the board on Tuesday, June 23, 2026, as the AI and semiconductor unwind morphed into a broad de‑risking that hit large caps, small caps, and high‑beta tech alike
Market at the close – indices and macro
U.S. stocks sold off broadly on Tuesday, June 23, 2026, as the AI and semiconductor unwind bled into the broader tape. The S&P 500 (^GSPC) fell 1.44% to close at 7,365.46, while the Dow Jones Industrial Average (^DJI) slipped 0.09% to 51,666.84, giving up early attempts to stabilize. The tech‑heavy Nasdaq Composite (^IXIC) led the decline, dropping 2.21% to 25,587.04, with growth, AI hardware, and chip names under heavy pressure. Small caps also joined the sell‑off, with the Russell 2000 (^RUT) finishing down 0.96% at 2,975.48, underscoring that today’s move was a broad de‑risking rather than a narrow mega‑cap tech story. Macro‑wise, the tape reflected less a single data shock and more a positioning reset. Investors are reassessing how much AI‑driven capex and semiconductor earnings can justify recent valuation extremes against a backdrop of higher‑for‑longer policy rates, an uneven global growth profile, and growing concerns that corporate guidance may begin to lag AI‑inflated expectations in the second half of the year.
AI and chips – from euphoria to risk‑off
The core equity story remains the cool‑off in AI and semiconductors, which has shifted from a tactical shakeout into a firmer valuation check. Chip leaders such as Nvidia (NVDA), Micron Technology (MU), Intel (INTC), and AMD (AMD), along with broader semiconductor baskets like the VanEck Semiconductor ETF (SMH) and leveraged products such as SOXL, came under heavy pressure as investors questioned how far AI‑related demand can stretch margins and multiples. This unwinding has begun to look self‑reinforcing. As crowded AI and chip trades roll over, systematic and leveraged strategies are forced to de‑risk, adding mechanical supply into already fragile order books. The narrative tug‑of‑war between “AI euphoria” and “AI phobia” is now being settled in price action: the Nasdaq’s more than 2% decline, alongside downside in the S&P 500, signals a pivot from “growth at any price” toward “show me the cash‑flows and durability.” The weakness is not confined to U.S. shores. Selling pressure in Korean, European, and other Asian chip names has broadened the move into a global AI/semiconductor reset, reinforcing that this is a cross‑border positioning event rather than a U.S.‑only correction.
Biotech focus – uniQure (QURE) taps public markets
Against this volatile macro and AI‑driven backdrop, gene therapy specialist uniQure N.V. (QURE) stepped in to raise growth capital, announcing a $150 million underwritten public offering this week of ordinary shares and pre‑funded warrants. The deal structure includes a 30‑day underwriters’ option to purchase additional shares, which could push gross proceeds toward roughly $172.5 million if fully exercised. Management has flagged the proceeds for late‑stage development and platform investment, with a particular focus on advancing its Huntington’s disease program AMT‑130 and other severe neurological and hematologic indications. In a market that is clearly discriminating between “science projects” and credible late‑stage platforms, QURE’s ability to tap the public markets at scale is noteworthy. It underscores that, even in a more risk‑averse tape, investors are still willing to fund differentiated IP and pipelines with tangible regulatory paths and value‑creating milestones. For biotech‑oriented investors in your audience, the juxtaposition is important: while high‑beta AI hardware is getting repriced, late‑stage gene‑therapy stories like uniQure can still access capital, provided they can clearly articulate clinical and commercial visibility.
Private equity and small‑business capital – Atlantic International / Circle8
In the private‑market and small‑business ecosystem, Atlantic International Corp. (ATLN, $1.33, +202.41%) and its Circle8 Group platform continue to illustrate where capital remains patient. Atlantic’s acquisition of Circle8 earlier this year created an integrated global workforce‑solutions platform with roughly $1.2 billion in revenue, spanning staffing, technology, and services. Subsequent multi‑year contracts and minimum‑commitment deals show that structured, recurring‑revenue models are still attracting sizable institutional and corporate capital. Today, they announced that Seven Stars B.V., a company within its Circle8 Group platform, has been awarded a four-year framework agreement by the Dutch Vehicle Authority (RDW) for the provision of specialized ICT (Information and Communications Technology) professionals. Seven Stars secured the contract through a competitive procurement process involving sixteen participants. Based on the procurement documentation, the framework agreement represents a minimum contract value of approximately $52 million over its four-year term. This award follows Circle8 Group’s recently announced public sector contract award with an estimated value of approximately $380 million and further demonstrates the platform’s ability to secure large-scale assignments in highly competitive markets.
VP Watchlist Updates
Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $8.33, +1.34%.
Eupraxia Pharmaceuticals Inc. (EPRX, $6.39), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”
Modular Medical, Inc. (NASDAQ:MODD, $4.29), a leader in innovative, patient-centric insulin delivery, announced (June 4) the launch of PivotPump.com, a patient-focused website designed to support individuals seeking a simpler path to insulin pump therapy. This launch follows the Company’s receipt of U.S. Food and Drug Administration (“FDA”) clearance in April 2026 for its Pivot™ insulin delivery system. The FDA clearance represents a significant milestone in Modular Medical’s strategy to expand access to insulin pump technology, particularly among individuals historically underserved by existing solutions. The Company remains on track for commercial launch in the fall of 2026. Pivot is designed for people living with diabetes who rely on daily insulin injections, as well as those who have encountered technological, usability, or cost-related barriers with traditional pump systems. The system emphasizes simplicity and ease of use for the patient and full access to clinical information for the clinician to reduce adoption friction. The PivotPump.com website provides accessible, educational content on insulin pump therapy and highlights the Company’s focus on real-world usability and supporting patients in evaluating and adopting pump-based diabetes care.
Similarweb Ltd. (NYSE: SMWB, $4.97), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR) and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.
The Sources
- Stock Market News for Jun 23, 2026 – Yahoo Finance[finance.yahoo]
- How Major US Stock Indexes Fared Tuesday 6/23/2026 – Yahoo Finance[finance.yahoo]
- Nasdaq Futures Fall 2% on Tech Worries, Fed Hike Bets – Reuters via Yahoo/Investing[finance.yahoo]
- Markets News, June 23, 2026: Stocks Fall as Tech Sell-Off Expands to Memory, Chips – Investopedia[investopedia]
- Stock Market News, June 23, 2026: Nasdaq and S&P 500 End Sharply Lower – MarketWatch Live Blog[marketwatch]
- Stock Market Today: Tech Slide Deepens as AI Fears Get Worse – Wall Street Journal Live Coverage[wsj]
- US AI Stock Sell-Off Shakes Markets from Wall Street to Asia – The Guardian[theguardian]
- Micron Technology Shares Plunge 13% as Global Chip Selloff Deepens – Livemint[livemint]
- One Factor May Keep Chip Stocks on a Roller Coaster – CNBC[cnbc]
- uniQure Announces $150 Million Proposed Public Offering – BioSpace[biospace]
- uniQure Launches $150 Million Public Share Offering – StreetInsider[streetinsider]
- UniQure Announces Planned $150 Million Public Offering – MarketScreener[marketscreener]
- Atlantic International Corp. Acquires Circle8 Group – Yahoo Finance[finance.yahoo]
- Atlantic International Expands its $1.2 Billion Revenue Platform – Yahoo Finance[finance.yahoo]
- Atlantic International Corp. (ATLN) Stock Price, News, Quote & History – Yahoo Finance[finance.yahoo]
Stay Updated with Vista Partners
Subscribe to receive market insights, investing ideas, and the latest updates directly in your inbox.
